We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 81.64%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$2.41B 23.65%
45,711,856
+1,611,562
+4% +$96.9M
INCY icon
2
Incyte
INCY
$25.5B
$2.36B 23.1%
23,499,087
+189
+0% +$18.4K
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$801M 7.85%
6,543,295
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.45B
$745M 7.3%
25,819,768
– –
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$405M 3.97%
13,770,302
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$398M 3.9%
4,806,483
– –
DBVT
7
DBV Technologies
DBVT
$824M
$194M 1.9%
550,956
– –
NGNE icon
8
Neurogene
NGNE
$656M
$174M 1.71%
526,805
– –
ONC
9
BeOne Medicines Ltd
ONC
$34.2B
$112M 1.09%
3,673,175
+1,760,495
+92% +$55.3M
ABBV icon
10
AbbVie
ABBV
$469B
$106M 1.04%
1,685,994
-12,657,364
-88% -$773M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.48B
$69.4M 0.68%
10,963,944
– –
AMRN
12
Amarin Corp
AMRN
$297M
$68.3M 0.67%
1,108,475
+76,951
+7% +$4.89M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$66.3M 0.65%
486,565
– –
ONCE
14
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$65.8M 0.64%
1,318,341
– –
ACOR
15
DELISTED
Acorda Therapeutics
ACOR
$62.1M 0.61%
27,515
-2,994
-10% -$7.12M
AKAO
16
DELISTED
Achaogen Inc
AKAO
$59.7M 0.58%
4,582,382
+4,482,382
+4,482% +$30.7M
AAAP
17
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$58M 0.57%
2,167,137
+1,137,890
+111% +$38.3M
NVTA
18
DELISTED
Invitae Corporation
NVTA
$57.9M 0.57%
7,288,300
+733,333
+11% +$5.48M
CERS icon
19
Cerus
CERS
$585M
$56.8M 0.56%
13,053,275
– –
EXEL icon
20
Exelixis
EXEL
$14.2B
$44.8M 0.44%
3,003,569
-1,925,925
-39% -$27.8M
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$34.7M 0.34%
895,422
– –
HRTX icon
22
Heron Therapeutics
HRTX
$92.7M
$31.2M 0.31%
2,383,569
-473,681
-17% -$7.43M
ARAV
23
DELISTED
Aravive, Inc. Common Stock
ARAV
$28.6M 0.28%
320,141
-35,567
-10% -$2.69M
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$27.4M 0.27%
2,466,702
– –
PGNX
25
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$27.2M 0.27%
3,150,808
-500,000
-14% -$3.7M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Baker Bros. Advisors held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Baker Bros. Advisors's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Baker Bros. Advisors's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Baker Bros. Advisors fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 7 in Q4 2016.
  • Baker Bros. Advisors's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.